2012 ALGORITHM FOR MANAGEMENT OF ADVANCED OVARIAN CANCER Bradley J. Monk, MD, FACS, FACOG Professor and Director Division of Gynecologic Oncology Department.
C. Schuhmacher, P.M. Schlag, F. Lordick, W. Hohenberger, J. Heise, C. Haag, S. Gretschel, M. Mauer, M.P. Lutz, J.R. Siewert Neoadjuvant chemotherapy versus.
Renal Cancer: Front line therapy Walter Stadler. Pathology Clear cell (conventional) –Fuhrman grading 1-4 Papillary –Type 1 & 2 (by histology) OR Class.
Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.
Neoadjuvant Chemotherapy in Ovarian Cancer
Multiple Myeloma:2013 Update Genomies
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Putting Cancer in Check with Immunotherapy: Melanoma and Beyond Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer.
Ovarian Cancer Diagnosis Surgery First-line Chemotherapy Consolidation Platinum-sensitive Recurrence Surgery Chemotherapy Platinum-resistant Recurrence.
Renal Cancer: Front line therapy